Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + apatinib maintenance therapy in platinum-sensitive recurrent ovarian cancer
ChiCTR2600121505Phase 2Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Mar 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and Rivoceranib in epithelial ovarian cancer (EOC), sponsored by Anqing Municipal Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
olaparibRivoceranib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2600121505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121505.